Cantor Fitzgerald Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $120 to $130.
August 08, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Intra-Cellular Therapies and raises the price target from $120 to $130.
The raised price target and maintained Overweight rating from a reputable analyst at Cantor Fitzgerald is likely to positively impact ITCI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100